In conclusion, PCSK9-i therapy significantly improved lipid profile, PWV, and sexual function in FH male patients; moreover, ∆ MSHQ was significantly associated with ∆ LDL-C and ∆ PWV. Here, PCSK9 is linked to familial hyperaldosteronism.